Glenmark Pharmaceuticals Ltd
NSE:GLENMARK
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
770.1
1 812.45
|
Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one GLENMARK stock under the Base Case scenario is 1 029.95 INR. Compared to the current market price of 1 478.2 INR, Glenmark Pharmaceuticals Ltd is Overvalued by 30%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Glenmark Pharmaceuticals Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for GLENMARK cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Glenmark Pharmaceuticals Ltd
Balance Sheet Decomposition
Glenmark Pharmaceuticals Ltd
Current Assets | 74.3B |
Cash & Short-Term Investments | 18.3B |
Receivables | 18.6B |
Other Current Assets | 37.4B |
Non-Current Assets | 69.3B |
Long-Term Investments | 8.6B |
PP&E | 35.4B |
Intangibles | 13.3B |
Other Non-Current Assets | 12B |
Current Liabilities | 58.2B |
Accounts Payable | 25.4B |
Other Current Liabilities | 32.8B |
Non-Current Liabilities | 6.9B |
Long-Term Debt | 1.5B |
Other Non-Current Liabilities | 5.4B |
Earnings Waterfall
Glenmark Pharmaceuticals Ltd
Revenue
|
120.2B
INR
|
Cost of Revenue
|
-43.4B
INR
|
Gross Profit
|
76.9B
INR
|
Operating Expenses
|
-69B
INR
|
Operating Income
|
7.9B
INR
|
Other Expenses
|
-21B
INR
|
Net Income
|
-13.1B
INR
|
Free Cash Flow Analysis
Glenmark Pharmaceuticals Ltd
INR | |
Free Cash Flow | INR |
GLENMARK Profitability Score
Profitability Due Diligence
Glenmark Pharmaceuticals Ltd's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
Score
Glenmark Pharmaceuticals Ltd's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
GLENMARK Solvency Score
Solvency Due Diligence
Glenmark Pharmaceuticals Ltd's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Score
Glenmark Pharmaceuticals Ltd's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GLENMARK Price Targets Summary
Glenmark Pharmaceuticals Ltd
According to Wall Street analysts, the average 1-year price target for GLENMARK is 1 591.11 INR with a low forecast of 575.7 INR and a high forecast of 2 137.8 INR.
Dividends
Current shareholder yield for GLENMARK is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
GLENMARK Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Glenmark Pharmaceuticals Ltd. is a holding company, which engages in the development, manufacture and marketing of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra. The firm is primarily engaged in the business of developing, manufacturing and marketing of pharmaceutical products. The company focuses on manufacturing products across therapeutic areas of respiratory, dermatology and oncology. The company is involved in development of new chemical entities (NCEs) and new biological entities (NBEs). Its business segments include India, North America, Europe and Rest of the world. The company is focused on developing and marketing branded and generic formulations. Its products include FabiFlu, Ryaltris and Remo (Remogliflozin etabonate). Its FabiFlu is an antiviral medication to treat mild to moderate COVID-19. Its Ryaltris is a fixed-dose combination nasal spray of an antihistamine (olopatadine hydrochloride 665 microgram) and a steroid that treats symptoms associated with seasonal, as well as perennial allergic rhinitis. Its Remo is a sodium-glucose transport-2 (SGLT2) inhibitor for the type 2 diabetes.
Contact
IPO
Employees
Officers
The intrinsic value of one GLENMARK stock under the Base Case scenario is 1 029.95 INR.
Compared to the current market price of 1 478.2 INR, Glenmark Pharmaceuticals Ltd is Overvalued by 30%.